Design of chimeric peptide ligands to galanin receptors and substance P receptors.

Several chimeric peptides were synthesized and found to be high-affinity ligands for both galanin and substance P receptors in membranes from the rat hypothalamus. The peptide galantide, composed of the N-terminal part of galanin and C-terminal part of substance P (SP), galanin-(1-12)-Pro-SP-(5-11) amide, which is the first galanin antagonist to be reported, recognizes two classes of galanin binding sites (KD(1) less than 0.1 nM and KD(2) approximately 6 nM) in the rat hypothalamus, while it appears to bind to a single population of SP receptors (KD approximately 40 nM). The chimeric peptide has higher affinity towards galanin receptors than the endogenous peptide galanin-(1-29) (KD approximately 1 nM) or its N-terminal fragment galanin-(1-13) (KD approximately 1 microM), which constitutes the N-terminus of the chimeric peptide. Galantide has also higher affinity for the SP receptors than the C-terminal SP fragment-(4-11) amide (KD = 0.4 microM), which constitutes its C-terminal portion. Substitution of amino acid residues, which is of importance for recognition of galanin by galanin receptors, such as [Trp2], in the galanin portion of the chimeric peptide or substitution of ([Phe7] or [Met11]-amide) in the SP portion of chimeric peptide both cause significant loss in affinity of the analogs of galantide for both the galanin- and the SP-receptors. These results suggest that the high affinity of the chimeric peptide, galantide, may in part be accounted for by simultaneous recognition/binding to both receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  T. Bártfai,et al.  The novel high-affinity antagonist, galantide, blocks the galanin-mediated inhibition of glucose-induced insulin secretion. , 1992, European journal of pharmacology.

[2]  T. Bártfai,et al.  Linear and cyclic N-terminal galanin fragments and analogs as ligands at the hypothalamic galanin receptor. , 2009, International journal of peptide and protein research.

[3]  S. Watson,et al.  Tachykinin receptor types: Classification and membrane signalling mechanisms , 1991, Neurochemistry International.

[4]  V. Pieribone,et al.  M-15: high-affinity chimeric peptide that blocks the neuronal actions of galanin in the hippocampus, locus coeruleus, and spinal cord. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  I. Gozes,et al.  A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes , 1991, Brain Research.

[6]  G. Fisone,et al.  Activity of centrally administered galanin fragments on stimulation of feeding behavior and on galanin receptor binding in the rat hypothalamus , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[7]  K. Arai,et al.  Chimeric opioid peptides: tools for identifying opioid receptor types. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[8]  W. Pardridge,et al.  Beta-endorphin chimeric peptides: transport through the blood-brain barrier in vivo and cleavage of disulfide linkage by brain. , 1990, Endocrinology.

[9]  R. B. Merrifield,et al.  Antibacterial and antimalarial properties of peptides that are cecropin‐melittin hybrids , 1989, FEBS letters.

[10]  G. Fisone,et al.  N-terminal galanin-(1-16) fragment is an agonist at the hippocampal galanin receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[11]  I. Gozes,et al.  Vasoactive intestinal peptide potentiates sexual behavior: Inhibition by novel antagonist , 1989, Regulatory Peptides.

[12]  D. Le-Nguyen,et al.  Design and chemical synthesis of a 32 residues chimeric microprotein inhibiting both trypsin and carboxypeptidase A. , 1989, Biochemical and biophysical research communications.

[13]  N. Yanaihara,et al.  Structural requirements for galanin interaction with receptors from pancreatic beta cells and from brain tissue of the rat , 1989, Peptides.

[14]  N. Yanaihara,et al.  Structural requirement for galanin action in the pancreatic β cell line Rin m 5F , 1989 .

[15]  R. Quirion.  Multiple tachykinin receptors , 1985, Trends in Neurosciences.

[16]  J. Glowinski,et al.  Pharmacological characterisation of two tachykinin binding sites in the rat cerebral cortex , 1985, Neuropeptides.

[17]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.